Unknown

Dataset Information

0

Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.


ABSTRACT:

Introduction

Dulaglutide (Dula) is a once-weekly glucagon-like peptide-1 receptor agonist that efficiently reduces the level of glycated hemoglobin (HbA1c) in patients with type 2 diabetes (T2D). However, the durability of the glucose-lowering effect of the first injection of Dula (1st Dula) remains unclear.

Methods

This study had a retrospective, single-center, and single-arm design in a clinical setting and was conducted between April 2016 and March 2017. We investigated the changes and fluctuations in glucose level in 15 patients with T2D using a continuous glucose monitor, from 1 day before the first administration of Dula to 6 days thereafter.

Results

The mean glucose levels decreased significantly from 1 day before 1st Dula up to 5 days thereafter, whereas the standard deviation, mean amplitude of glucose excursion, and percentage of the glucose levels > 180 mg/dL were significantly improved only up to 3, 2, and 3 days after the 1st Dula, respectively, compared to those before administration.

Conclusion

The effect of blood glucose regulation after the 1st Dula did not continue for a whole week. These effects should be considered when adjusting for other hypoglycemic agents.

SUBMITTER: Matsushita M 

PROVIDER: S-EPMC6167306 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5481842 | biostudies-literature
| S-EPMC9529765 | biostudies-literature
| S-EPMC7376612 | biostudies-literature
| S-EPMC7137291 | biostudies-literature
| S-EPMC10512224 | biostudies-literature
| S-EPMC7383507 | biostudies-literature
| S-EPMC10764236 | biostudies-literature
| S-EPMC4898439 | biostudies-other
| S-EPMC10995440 | biostudies-literature
| S-EPMC9300526 | biostudies-literature